Age Related Macular Degeneration News and Research RSS Feed - Age Related Macular Degeneration News and Research

Blocking Slit2 protein prevents blood vessel development that causes vasoproliferative ocular diseases

Blocking Slit2 protein prevents blood vessel development that causes vasoproliferative ocular diseases

Vasoproliferative ocular diseases are responsible for sight loss in millions of people in the industrialised countries. Many patients do not currently respond to the treatment offered, which targets a specific factor, VEGF. A team of Inserm researchers at the Vision Institute (Inserm/CNRS/Pierre and Marie Curie University), in association with a team from the Yale Cardiovascular Research Center, have demonstrated in an animal model that blocking another protein, Slit2, prevents the pathological blood vessel development that causes these diseases. [More]
Current challenges in tackling macular degeneration: an interview with Mark Ackermann, AMD Alliance International

Current challenges in tackling macular degeneration: an interview with Mark Ackermann, AMD Alliance International

There are two forms of macular degeneration: the wet form and the dry form. The dry form is less challenging as it affects a smaller number of people and the disease progression is far slower... [More]
RetroSense Therapeutics receives Luis Villalobos Award

RetroSense Therapeutics receives Luis Villalobos Award

RetroSense Therapeutics, LLC, a Wayne State University start-up biotechnology company, has received the Luis Villalobos Award from the Angel Capital Association, the world's leading professional association for angel investors. [More]
Research: Stem cell injection may soon slow or reverse effects of age-related macular degeneration

Research: Stem cell injection may soon slow or reverse effects of age-related macular degeneration

An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai. Currently, there is no treatment that slows the progression of the disease, which is the leading cause of vision loss in people over 65. [More]
UC Davis' John S. Werner wins 2015 Verriest Medal from International Colour Vision Society

UC Davis' John S. Werner wins 2015 Verriest Medal from International Colour Vision Society

John S. Werner, a UC Davis neuroscientist and international authority on visual perception, has been selected to receive the 2015 Verriest Medal from the International Colour Vision Society for his contributions to understanding the structural and functional basis of color vision, how and why vision changes across the life span, and factors that contribute to loss of vision associated with disease. He will receive the award at the society's biennial symposium in Sendai, Japan, in July. [More]
Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) and Cellular Dynamics International, Inc. (CEO: Robert J. Palay), a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today announced that the two companies have entered into a definitive agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger. [More]
Regeneron announces FDA approval of EYLEA (aflibercept) Injection for diabetic retinopathy

Regeneron announces FDA approval of EYLEA (aflibercept) Injection for diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME. [More]
Loyola ophthalmologist recommends specific foods and supplements for healthy vision

Loyola ophthalmologist recommends specific foods and supplements for healthy vision

You may remember your mother telling you to eat your carrots; they are good for your eyes. Well, she was right. "Carrots are actually just one of the many foods, and supplements that contribute to good eye health," says James McDonnell, MD, pediatric ophthalmologist, Loyola University Health System. "In some cases, eyesight can actually be improved depending on what you eat." [More]
Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit. [More]
UTSA professor named Gold Fellow of the Association for Research in Vision and Ophthamology

UTSA professor named Gold Fellow of the Association for Research in Vision and Ophthamology

Andrew Tsin, professor of biology in the UTSA College of Sciences, has been named a Gold Fellow of the Association for Research in Vision and Ophthamology for his dedication and exemplary contributions in the field. Tsin will receive the honor at the 2015 ARVO Annual Meeting, May 3-7 in Denver. [More]
Oraya's IRay Radiotherapy system gets CE Mark to treat choroidal metastases

Oraya's IRay Radiotherapy system gets CE Mark to treat choroidal metastases

Oraya Therapeutics announced today that the Oraya IRay® Radiotherapy system has received a CE Mark extension for the treatment of choroidal metastases, a cancer in the eye, originating most commonly from primary sites in the breast or lung. [More]
Researchers discover retina protein crucial for vision

Researchers discover retina protein crucial for vision

Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the LSU Health New Orleans Neuroscience Center of Excellence, discovered a protein in the retina that is crucial for vision. The paper reports, for the first time, the key molecular mechanisms leading to visual degeneration and blindness. [More]
Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO). [More]
Omega-3 could supplement anti-VEGF treatment in AMD

Omega-3 could supplement anti-VEGF treatment in AMD

Pilot study findings suggest that taking omega-3 fatty acid supplements could increase the efficacy or reduce the needed frequency of anti-vascular endothelial growth factor treatment in patients with exudative age-related macular degeneration. [More]
‘Earliest’ characteristics presaging drusen-associated atrophy identified

‘Earliest’ characteristics presaging drusen-associated atrophy identified

Researchers have used spectral-domain optical coherence tomography to identify specific pathological changes that precede the development of drusen-associated atrophy in patients with age-related macular degeneration. [More]

Adaptive optics find reflectivity differences between drusen types in AMD

Adaptive optics provide insight into the differences in reflectivity between medium–large drusen and reticular pseudodrusen in patients with age-related macular degeneration, researchers report. [More]

Meta-analysis gives intravitreal ranibizumab vascular adverse risk profile

Intravitreal ranibizumab treatment for age-related macular degeneration does not elevate the risk of mortality, suggests a meta-analysis published in Ophthalmology. [More]
NYEE ophthalmologists offer prevention tips to observe AMD Awareness Month

NYEE ophthalmologists offer prevention tips to observe AMD Awareness Month

Macular degeneration is a major cause of irreversible vision loss in the United States and around the world. As many as 11 million Americans have some form of macular degeneration. [More]
EyePromise® eye vitamins offers education guide to promote awareness on AMD

EyePromise® eye vitamins offers education guide to promote awareness on AMD

Due to the aging Baby Boomer population, AMD, or Age-related Macular Degeneration, is expected to double by the year 2020. [More]
Reversing effects of early stage age-related macular degeneration may be possible

Reversing effects of early stage age-related macular degeneration may be possible

A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity. [More]
Advertisement
Advertisement